Wall Street analysts predict that Johnson & Johnson (NYSE:JNJ) will announce $19.38 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Johnson & Johnson’s earnings. The lowest sales estimate is $19.06 billion and the highest is $19.69 billion. Johnson & Johnson posted sales of $17.77 billion in the same quarter last year, which suggests a positive year over year growth rate of 9.1%. The business is expected to report its next earnings report on Tuesday, April 17th.
On average, analysts expect that Johnson & Johnson will report full-year sales of $19.38 billion for the current fiscal year, with estimates ranging from $80.96 billion to $81.48 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $84.83 billion per share, with estimates ranging from $83.98 billion to $85.79 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The firm had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. During the same quarter in the previous year, the company posted $1.58 EPS. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year.
In other news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.19% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in JNJ. Landmark Financial Advisors LLC grew its stake in Johnson & Johnson by 0.4% in the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after acquiring an additional 7 shares during the period. Paradigm Financial Advisors LLC grew its stake in Johnson & Johnson by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $350,000 after acquiring an additional 9 shares during the period. Premier Asset Management LLC grew its stake in Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after acquiring an additional 12 shares during the period. Lbmc Investment Advisors LLC grew its stake in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $492,000 after acquiring an additional 14 shares during the period. Finally, Halbert Hargrove Russell LLC grew its stake in Johnson & Johnson by 0.4% in the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock valued at $466,000 after acquiring an additional 15 shares during the period. 67.35% of the stock is owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (JNJ) traded down $2.03 on Friday, reaching $132.32. The company’s stock had a trading volume of 6,770,089 shares, compared to its average volume of 8,690,000. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a 52-week low of $120.95 and a 52-week high of $148.32. The company has a market cap of $355,000.00, a P/E ratio of 24.37, a price-to-earnings-growth ratio of 2.17 and a beta of 0.77.
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were paid a $0.84 dividend. The ex-dividend date of this dividend was Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.88%.
ILLEGAL ACTIVITY WARNING: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3262365/johnson-johnson-jnj-expected-to-post-quarterly-sales-of-19-38-billion.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.